Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.44 |
| ▸ | RORC | P51449 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.36 |
| ▸ | CECR2 | Q9BXF3 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21598714 | 0.84 | ALDH1A1 (0.47) | MALT1ALDH1A1IDO1MAPTMEN1 | |
| SCHEMBL21598705 | 0.83 | MALT1 (0.46) | MALT1ALDH1A1IDO1MEN1KMT2A | |
| SCHEMBL21598728 | 0.80 | MALT1 (0.49) | MALT1ALDH1A1MAPTSMN1; SMN2L3MBTL1 | |
| SCHEMBL1008664 | 0.75 | RORC (0.52) | RORCALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1817504 | 0.75 | RORC (0.47) | RORCALDH1A1IDO1ATMMAPT | |
| SCHEMBL28134648 | 0.73 | RORC (0.51) | MALT1RORCALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL21598719 | 0.72 | PLAU (0.35) | MALT1ALDH1A1MEN1KMT2A | |
| SCHEMBL1675548 | 0.69 | RORC (0.47) | RORCALDH1A1IDO1SMN1; SMN2PTK2 | |
| SCHEMBL27020286 | 0.68 | ALDH1A1 (0.41) | ALDH1A1MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL27416264 | 0.67 | RORC (0.45) | RORCALDH1A1SMN1; SMN2L3MBTL1PTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3810609-A1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | Janssen Pharmaceutica NV (BE) | 2021-04-28 | — | — | EP | disclosed |
| US-10888550-B2 | Pyrazole derivatives as MALT1 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2021-01-12 | — | — | US | disclosed |
| WO-2019243965-A1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-12-26 | — | — | WO | disclosed |
| WO-2019243965-A1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-12-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10888550-B2 | Pyrazole derivatives as MALT1 inhibitors | MALT1, PPP3R1, SQSTM1 | MALT1 1/4885RORC 1645/4885ALDH1A1 2588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.